TOWNHALL
RAIA's Gift to Big Tech and China

If you set out to give a gift to Big Tech and the Infringer Lobby, worsen the Administrative State and advantage innovation adversaries like China, it would take some doing to check all these boxes more fully than S. 2891, the “Restoring the America Invents Act.”

ECONOMIC STANDARD
The Patent Eligibility "Quagmire"

A federal judge calls the status of patent-eligible subject matter “validity goulash.” A former chief judge of the Federal Circuit Court of Appeals calls it “a quagmire.” The patent eligibility mess is one of the most urgent crises in patent law and policy.

IP WATCHDOG
Don't Turn Bayh-Dole March-In Into Price Controls

Thirty-one signatories from 29 center-right public policy organizations have warned HHS Sec. Becerra, “Using march-in rights to regulate prices would have a chilling effect on drug development and on other innovative sectors.”

ECONOMIC STANDARD
How to Retain U.S. R&D Lead on China

Proposals in Congress would bar U.S. companies from licensing chips to Chinese end-user device companies and restrict U.S. R&D firms from involvement in global standards-development organizations where China’s state-run companies also participate.  Intended to cripple China’s strategic microchip gains, they would actually cripple U.S. leadership in the most critical part of the chip space.

WALL STREET JOURNAL
When Will the Doctors Step Up?

Joel Zinberg’s op-ed “Covid Patients Suffer as Bureaucrats Try to Practice Medicine” (Feb. 8) highlights a sad, avoidable contrast between the Biden administration’s red-tape approach and the property rights-centric, market-based success of Operation Warp Speed.

REAL CLEAR MARKETS
Gov't. Regulation Can't Secure U.S. Supply Chain

H.R. 4521, the House-passed America COMPETES Act, sets up a Mother-May-I gatekeeper that will stifle U.S. innovation and competitiveness. Empowering unelected officials to decide whether American companies can invest overseas won't stop China, but it will damage America's economy and plunge us into a vicious retaliatory cycle with other nations.

ECONOMIC STANDARD
A Better Way to Go After Big Tech

You’d expect conservatives to approach reining in Big Tech consistent with free enterprise, property rights and innovation principles. Better to strengthen IP than to weaponize antitrust.

WASHINGTON TIMES
Combating China’s Ambitions Requires Strong Property Rights

.One of the most significant challenges facing our nation today in the emerging battle with China. We must take action to ensure that China does not become the dominant force in global technology leaership.

CAPITALISM MAGAZINE
The Founders’ Inventive Constitutional Brilliance

This Constitution Day, thank the Founders for stimulating ingenuity by applying “the fuel of interest to the fire of genius.” And while you’re at it, thank an inventor.

THE HILL
Supreme Court Ruling Is a Win for Property Rights

The U.S. Supreme Court took a major step in upholding these fundamental rights by striking down the Centers for Disease Control and Prevention’s (CDC) latest eviction moratorium extension. 

ISSUES & INSIGHTS
Biden Executive Order Missteps Empower China

The executive order calls for “review” of the 2019 Policy Statement on Remedies for Standards-Essential Patents Subject to Voluntary F/RAND Commitments. This foreshadows a return to a disruptive Obama-era SEP policy.

REAL CLEAR MARKETS
Biden's Competition Order Worse Than Illness

President Biden made a big deal in the rollout of his executive order on market consolidation about the price of prescription drugs.  The order weaponizes antitrust and damages the patent system.  That’s not strong medicine.  It’s deadly poison.

IP WATCHDOG
An Evidence-Based Look at ‘Patent Quality’

“'Patent troll' scaremongering and that narrative’s flimsy evidentiary basis are alive and well and back in use with a vengeance by those who don’t respect patents. But conservative thought leaders are giving an evidence-based perspective on the necessity of reliable patents, meaningful patent rights and how our patent system suffers from 'reforms.'”

WASHINGTON TIMES
Supreme Court Gives China Innovation Advantage

"In Supreme Court session postmortems, don’t expect mention of any change in course from the vast injury it’s inflicted over the past dozen years on patent eligibility. Why does this matter? Because the high court has done as much or more than anything to give China an advantage in innovation and industrial competitiveness over the U.S."

REAL CLEAR MARKETS
Biden Hits Property Rights to Boost Competition

"President Biden’s executive order, 'Promoting Competition in the American Economy,' purports to promote competition. Let’s just say the order presumes a whole lot. Its false presumptions lead to policies that weaponize a blunt instrument: antitrust."

TOWNHALL
Time to Strengthen Our Patent System

"We should give permanency to measures that strengthen U.S. patent rights.  Certainty and reliability of patent policies critically affecting American innovation shouldn’t be subject to radical shifts from one administration to the next."

REAL CLEAR POLICY

China's Patent Gain is Our Loss

"China has ramped up a multipronged, whole-of-society strategy to beat America and the West. This goes well beyond mere copying and IP theft. Other prongs include subsidies for Chinese companies, predatory pricing, import restrictions, a biased regulatory regime and economic espionage."

INSIDE SOURCES

Envious Countries Pushing IP Shakedown at WTO

The WTO ploy seeks to waive 1994 Trade-Related Aspects of Intellectual Property Rights Agreement obligations to protect intellectual property for any inventions related to COVID-19. If successful, the foreign expropriation of U.S. companies’ intellectual property wouldn't be limited to biomedical innovation and would reduce innovation.

REAL CLEAR POLICY

Don't Impose Foreign Price Controls on Prescriptions

Biotech, pharmaceutical, and medical provider organizations have sued the Trump administration over an overreaching rule, called "Most Favored Nation," that imports foreign government-run medical systems’ price controls as a gambit to lower prescription drug prices.  MFN won't.